With Two BCMA-Targeting Myeloma Treatments, Which Should Be First Choice?

Experts Weigh In On Positioning BMS/Bluebird’s Abecma And GSK’s Blenrep

 
• By Alaric DeArment
Open Book Of prostate multiple myeloma, Conceptual Image - Image
With two BCMA-targeting myeloma therapies available, the question now is how to position them in treatment • Source: Shutterstock

More from Market Snapshot

More from Scrip